Product image of Lenalidomide Krka (Lenalidomide) supplied by GNH India

Lenalidomide Krka

Active Ingredient:
Lenalidomide
Origin:
EU

Lenalidomide Krka (Lenalidomide)

Lenalidomide, the active ingredient in Lenalidomide Krka, is an immunomodulatory drug (IMiD) presented as an oral tablet for oral use. It is indicated for the treatment of certain blood cancers, including multiple myeloma and myelodysplastic syndromes, in adult patients.
GNH India supplies Lenalidomide Krka as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Krka, D.D., Novo Mesto

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Lenalidomide is an immunomodulatory antineoplastic that targets malignant plasma cells and dysplastic bone‑marrow clones.

  • Multiple myeloma: improves progression‑free and overall survival in eligible patients.
  • Myelodysplastic syndromes (del(5q) cytogenetic abnormality): reduces transfusion dependence and may achieve cytogenetic remission.
  • Relapsed or refractory multiple myeloma: provides an additional therapeutic option after prior therapies have failed.

How It Works

  • Lenalidomide binds to the cereblon component of the CRL4‑CRBN E3 ubiquitin ligase complex, altering substrate specificity and promoting ubiquitination of transcription factors such as Ikaros and Aiolos. This leads to anti‑angiogenic, immunomodulatory, and anti‑proliferative effects that inhibit malignant cell growth and enhance immune‑mediated tumor clearance.

Side Effects

Lenalidomide may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects

  • Fatigue: persistent tiredness affecting daily activities.
  • Neutropenia: reduced neutrophil count increasing infection risk.
  • Thrombocytopenia: low platelet count leading to easy bruising.
  • Diarrhea: loose stools that may be mild to moderate.
  • Constipation: difficulty passing stools.
  • Rash: skin irritation or erythema.

Serious or Rare Side Effects

  • Venous thromboembolism: blood clots in deep veins or lungs.
  • Severe neutropenia: markedly low neutrophils requiring medical intervention.
  • Severe thrombocytopenia: dangerously low platelets.
  • Secondary primary malignancies: emergence of new cancers.
  • Severe liver injury: marked elevation of hepatic enzymes.
  • Hypersensitivity reactions: anaphylaxis or severe skin reactions.

Precautions & Warnings

Before initiating therapy, clinicians should evaluate patient‑specific risk factors and monitor laboratory parameters.

  • Pregnancy contraindication: teratogenic; avoid use in pregnant women and ensure effective contraception.
  • Thrombosis risk: assess for prior clotting events; consider prophylactic anticoagulation when appropriate.
  • Hematologic monitoring: perform regular complete blood counts to detect cytopenias.
  • Renal impairment: adjust dosing in patients with reduced kidney function.
  • Drug interactions: review concomitant medications for CYP3A4 modulators.
  • Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Avoid Interactions

Lenalidomide can interact with several drug classes, requiring careful management.

Major Interactions (Avoid)

  • Thalidomide: combined use increases teratogenic and neurotoxic risk.
  • Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce lenalidomide exposure.
  • Anticoagulants (warfarin, DOACs): heightened risk of thromboembolic events.

Moderate Interactions (Monitor Closely)

  • CYP3A4 substrates (e.g., cyclosporine, tacrolimus): may require dose adjustment.
  • NSAIDs: increased potential for gastrointestinal bleeding.
  • Live vaccines: attenuated immune response; avoid concurrent administration.

Frequently Asked Questions

Lenalidomide Krka is prescribed for adult patients with multiple myeloma and for those with myelodysplastic syndromes that carry a del(5q) chromosomal abnormality. In both settings, it helps control disease progression and can reduce the need for blood transfusions.

The drug binds to cereblon, a component of the CRL4‑CRBN E3 ubiquitin ligase complex, altering its activity. This leads to the degradation of specific transcription factors, resulting in anti‑angiogenic, immunomodulatory, and anti‑proliferative effects that suppress malignant cell growth.

The dosage of Lenalidomide Krka is individualized by the prescribing clinician based on the patient’s disease, prior therapies, renal function, and blood‑count parameters. Only a qualified health professional should determine the appropriate regimen.

Lenalidomide is classified as pregnancy category X because it is teratogenic and can cause fetal harm. It is contraindicated in pregnancy, and effective contraception is required for both men and women of child‑bearing potential. Use during breastfeeding is not recommended.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Lenalidomide belongs to the immunomodulatory drug class, similar to thalidomide and pomalidomide. Compared with thalidomide, lenalidomide generally has a more favorable side‑effect profile, especially regarding neuropathy, while offering comparable anti‑myeloma activity. Pomalidomide is often reserved for patients who have progressed after lenalidomide therapy.

Store Lenalidomide Krka tablets at temperatures below 25 °C (77 °F). Keep the product in its original container, protect it from moisture and direct sunlight, and avoid storing it in bathrooms or near heat sources.

Lenalidomide Krka is taken orally, usually once daily in the evening with or without food, as directed by the prescriber. The tablets should be swallowed whole with water and not crushed or chewed.

The most serious risks include severe neutropenia and thrombocytopenia, which can lead to infections or bleeding, and venous thromboembolism, which may cause life‑threatening clots. Additionally, the drug is teratogenic and can cause secondary primary malignancies in rare cases.

Lenalidomide should not be used by pregnant women or individuals who are not using effective contraception. Patients with uncontrolled infections, severe hepatic impairment, or known hypersensitivity to lenalidomide or its excipients should also avoid this medication.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Lenalidomide

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT